Evidence map›Paper›PMID 42451374›Full record

ReviewSensors (Basel, Switzerland)2026

Gold- or Silver-Nanoparticle SERS Platforms for Plasma-Based Diagnostics and AI-Driven Analysis.

Gideon L Elizur, Alexandre Canhoto, Gabriela Soares, Lucio Studer Ferreira, Eulália Pereira, Ricardo Franco

Abstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gideon L ElizurAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0009-0006-4900-4610
Alexandre CanhotoAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.
Gabriela SoaresISCTE-University Institute of Lisbon, 1649-026 Lisbon, Portugal.ORCID 0000-0002-0232-9489
Lucio Studer FerreiraCOPELABS, Lusófona University, Campo Grande 376, 1749-024 Lisbon, Portugal.ORCID 0000-0002-0235-2531
Eulália PereiraLAQV/REQUIMTE-Laboratório Associado para a Química Verde/Rede de Química e Tecnologia, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.ORCID 0000-0003-2086-5696
Ricardo FrancoAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0000-0002-5139-2871

Funding

Fundação para a Ciência e Tecnologia LA/P/0140/2020 (DOI identifier 10.54499/LA/P/0140/2020)Fundação para a Ciência e Tecnologia UID/04378/2025 (DOI identifier 10.54499/UID/04378/2025)Fundação para a Ciência e Tecnologia UID/PRR/04378/2025 (DOI identifier 10.54499/UID/PRR/04378/2025)
6 · The paper itself

Abstract

Surface-enhanced Raman spectroscopy (SERS) has emerged as a highly promising analytical technique for disease diagnostics due to its exceptional sensitivity, molecular specificity, and ability to detect a broad range of biomarkers in complex biological matrices. This review provides a comprehensive overview of gold- and silver-nanoparticle-based SERS platforms for plasma disease diagnostics, covering advances in plasmonic nanostructures, biological sample analysis, biomarker detection, and AI-driven spectral data processing. Particular emphasis is placed on the application of SERS to clinically relevant biofluids, especially plasma, where the technique has demonstrated considerable potential for detecting diseases such as cancer, inflammatory disorders, and neurological conditions. The review also critically examines the major challenges currently limiting the clinical translation of SERS technologies. These include variability associated with substrate fabrication, matrix-induced signal fluctuations, limited interlaboratory reproducibility, and the lack of standardized protocols for spectral preprocessing and data analysis. Strategies proposed to address these issues are discussed, including comprehensive post-synthesis substrate characterization, optimization of biological sample preparation, advanced spectral preprocessing workflows, and the integration of machine learning and artificial intelligence algorithms to improve diagnostic robustness and reproducibility. Collectively, the advances summarized in this review indicate that SERS-based diagnostic technologies are rapidly progressing beyond proof-of-concept studies toward clinically applicable systems. Continued interdisciplinary collaboration and standardization efforts will be essential to bridge the remaining gap between experimental SERS methodologies and routine clinical implementation.

Indexed as

Artificial IntelligenceGoldMetal NanoparticlesSilverSpectrum Analysis, RamanBiomarkersHumansBiomarkersGoldSilverartificial intelligencegold nanoparticlesliquid biopsymachine learningplasma diagnosticsplasmonic nanoparticlessilver nanoparticlessurface-enhanced Raman spectroscopy (SERS)

Identifiers

PMID42451374
PMCPMC13364064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.